Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7389 Liposomal Formulation in Solid Tumors
NCT03207672Phase 1Active, not recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Aug 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of eribulin in solid tumor, breast cancer, adenoid cystic carcinoma (ACC) and 3 more (2 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Maximum Tolerated Dose. Started Aug 2017; status: active, not recruiting.
02
Drugs
eribulin
03
Conditions
solid tumorbreast canceradenoid cystic carcinoma (ACC)gastric cancer (GC)esophageal cancer
Beyond the preview
Go deeper on NCT03207672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03207672.